wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38829545-63CB1502-4248-4675-A5B1-B83D1787EA7A
Q38829545-63CB1502-4248-4675-A5B1-B83D1787EA7A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38829545-63CB1502-4248-4675-A5B1-B83D1787EA7A
Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.
P2860
Q38829545-63CB1502-4248-4675-A5B1-B83D1787EA7A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38829545-63CB1502-4248-4675-A5B1-B83D1787EA7A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0ad4ad981232414efde32414ecc8e86c03629508
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.